T-cell receptor beta variable 7-9 (TRBV7-9) (TRBV7-9)

T-cell receptor beta variable 7-9 (TRBV7-9) is a protein component of the T-cell receptor (TCR) complex, specifically forming part of the variable region of the beta chain (IMGT, 2023). The TCR is a membrane-bound heterodimer found on T-lymphocytes that recognizes antigenic peptides presented by major histocompatibility complex (MHC) molecules, a process essential for the adaptive immune response (UniProt, 2023). TRBV7-9 is one of many V-segments that undergo somatic recombination to generate a diverse TCR repertoire capable of recognizing a wide array of pathogens (NCBI Gene, 2023). This specific Vβ segment is clinically significant because it can be selectively targeted by superantigens, such as Staphylococcal enterotoxins, which bypass normal antigen processing to cause massive, non-specific T-cell activation and cytokine storms (Fraser, 2011). In therapeutic development, TRBV7-9 is explored as a target for monoclonal antibodies or TCR-based therapies to treat T-cell malignancies or autoimmune diseases characterized by the expansion of specific T-cell clones (Maciocia et al., 2017). Monitoring the expression of TRBV7-9 serves as a biomarker for immune profiling and diagnosing certain lymphoproliferative disorders (van Dongen et al., 2003). The target is also relevant in the study of toxic shock syndrome and other inflammatory conditions where specific Vβ families are disproportionately involved. Therapeutic strategies targeting this molecule aim to either neutralize superantigen effects or deplete pathogenic T-cell populations while sparing the rest of the immune system.

Other names

TCR Vβ7.9TCR Vbeta 7.9TRBV7-9T-cell receptor beta chain variable region 7-9T cell receptor beta variable 7-9

Selective binding to the Vβ7-9 region of the T-cell receptor to modulate T-cell activation or induce clonal depletion.